Table 2 Comparison of the 20 cases and 40 controls in univariate analysis with conditional logistic regression
Cases (n= 20) | Controls (n= 40) | P | |
|---|---|---|---|
Female, n | 19 | 34 | 0.27 |
No-low/moderate-high rheumatic disorder activity, n | 11/7 | 20/20 | 0.67 |
TJA surgery on affected or matched joint within the last year, n | 8 | 5 | 0.03† |
- of which primary TJA, n/TJA revision, n | 5/3 | 3/2 | |
- after TNFα-blockers introduction | 6 of 8 | 5 of 5 | |
- after TNFα-blocker withdrawal ≥5 half-lives | 1 of 6 | 4 of 5 | 0.08 |
Previous TJA infection, n | 3 | 0 | 0.08 |
- of which same TJA involved, n | 2 | - | - |
Main comorbidities, n | |||
- Diabetes mellitus | 2 | 1 | 0.26 |
- Bronchiectasis | 0 | 1 | 0.99 |
- Cirrhosis | 0 | 0 | 1 |
- Cancer/hemopathy | 0 | 2 | 0.99 |
- HIV | 0 | 0 | 1 |
- Chronic renal failure | 1 | 2 | 1 |
- Hypogammaglobulinemia | 1 | 1 | 0.88 |
Current TNFα-blocker: | |||
- Infliximab/etanercept/adalimumab, n | 7/5/8 | 13/15/12 | 0.70 |
- Duration of exposition to the current TNFα- | 26.0 ± 24.1 | 39.0 ± 24.6 | 0.06 |
blocker (months) * | |||
Number of prior TNFα-blockers * | 0.5 ± 0.7 | 0.6 ± 0.7 | 0.69 |
Total duration of exposition to any TNFα-blockers (months) * | 32.0 ± 25.6 | 48.6 ± 25.2 | 0.07 |
Oral intake of steroids * (mg/d) | 9.5 ± 7.3 | 5.3 ± 3.9 | 0.02† |
Oral intake of steroids ≥10 mg/d, n | 7 | 7 | 0.06 |
Intravenous infusion of steroids last year, n | 2 | 1 | 0.75 |
Current DMARDs, n | |||
- Methotrexate | 14 | 26 | 0.71 |
- Leflunomide | 1 | 5 | 0.99 |
- Azathioprine | 0 | 2 | 0.40 |